RxDoctor Payments Data

Rasha Bahri

Family · Troy, MINPI 1598495574

Payments from drug & device makers

$2,964in general payments, 2019–2025

Across 137 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$388
  • Gilead$233
  • Ardelyx, Inc.$232
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$210
  • Agios Pharmaceuticals, Inc.$193
  • Takeda Pharmaceuticals U.S.A., Inc.$189
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$2,964100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,964 in reported general payments places this provider in the 85th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$28,208
Medicare patients
91
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide114$74,299
JardianceEmpagliflozin43$38,153
TrulicityDulaglutide26$27,873
OzempicSemaglutide21$27,520
FarxigaDapagliflozin Propanediol21$15,686
EliquisApixaban13$13,431
TradjentaLinagliptin15$7,512
Diclofenac Sodium91$2,820
Pantoprazole Sodium95$1,799
Omeprazole142$1,052
Potassium Chloride44$939
Atorvastatin Calcium151$863
Levothyroxine Sodium92$809
Famotidine72$769
Metformin Hcl165$760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$388$74,299114 claims
Novo NordiskOzempic$151$27,52021 claims
PfizerEliquis$184$13,43113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,657 family providers in Michigan.

Other family in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →